Acquired Brain InjuryNCT05440682
Connectivity in Cranioplasty
A study testing CP group in people with Acquired Brain Injury and Traumatic Brain Injury, run by Azienda Usl di Bologna at 1 site in Italy.
Trial summary
An Exploratory Interventional study to assess the effects of cranioplasty on brain network connectivity, neuropsychological and motor functioning in patients with severe acquired brain injury with pre-, post-cranioplasty and 6 months follow-up assessments. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Acquired Brain Injury, Traumatic Brain Injury, Ischemic Stroke
- What is being tested?
- CP group
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteItaly
- Study dates
- 27 Oct 2020to 27 Apr 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of sABI, a neurological condition due to a severe acquired brain damage (i.e., traumatic brain injury, ischemic stroke, hemorrhagic stroke) with a coma lasting at least 24 hours, according to a Glasgow Coma Scale equal or lower than 8 and/or complex and severe neurological disabilities treatable only in high specialty neurehabilitative settings.
- Early DC, within 24 h;
- Age between 18 and 75 years;
- Intra-hospital rehabilitation setting (ordinary hospitalization or day hospithal);
- Informed consent agreement.
Who cannot join
- Medical instability at enrollment, defined as the acute onset of an unexplained derangement of vital parameters (i.e., temperature, blood pressure, pulse rate, respiratory rate, oxygen saturation, level of responsiveness) outside the normal range (for example, fever, acute internist conditions, etc.) and/or the onset of any new medical condition requiring unexpected additional diagnostic procedures and treatments (for example, severe pain, reduction of urinary output, etc.);
- Post-traumatic agitation;
- Dehiscence, in progress, of the DC surgical wound;
- CP already performed;
- Magnetic Resonance Imaging (MRI) absolute contraindications.
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
Irccs - Istituto Delle Scienze Neurologiche
Bologna, 40139
Fabio La Porta, Md, 051 622 5111, fabiolaporta@mail.com
Fabio La Porta, 051 622 5111, fabiolaporta@mail.com
About this study
Official title: Structural and Functional Connectivity as Outcome Markers of Cranioplasty Following Decompressive Craniectomy
An Exploratory Interventional study to assess the effects of cranioplasty on brain network connectivity, neuropsychological and motor functioning in patients with severe acquired brain injury with pre-, post-cranioplasty and 6 months follow-up assessments.
Read the detailed description
BACKGROUND: Cranioplasty (CP) refers to the surgical reconstruction of the cranial defect secondary to Decompressive Craniectomy (DC). The aim of this intervention is not only to restore cranial cosmesis and the normal cerebral protection, but also to facilitate neurological rehabilitation.
Clinical improvements after CP, may occur as early as 4 days after the surgical reconstruction of the cranial vault and may include vigilance/consciousness, sensorimotor and cognitive functioning. In particular, several studies showed relevant neurological improvement of motor and cognitive impairments as well as in the disability level in severe acquired brain injury (sABI) patients treated with DC in the acute phase. To date, it is not possible to predict the extent of the expected improvement after CP, and the effects in terms of long-term functional outcome appears to be variable from subject to subject.
The CO-CRAN (COnnectivity in CRANioplasty) study is based on the experimental hypothesis that the extent of recovery could be significantly correlated with the degree of integrity of the neural network, in relation to the primary damage, of the cerebral hemisphere ipsilateral to craniectomy. It is assumed that if the neural network is relatively intact, the extent of the recovery could be maximal. Conversely, when there is an extensive functional impairment of the underlying craniectomy flap, the impairment of the neural network does not allow a maximum recovery.
AIM: The aim of the study is to investigate possible morpho-functional neuroimaging determinants that may be predictive of post-cranioplasty recovery in patients with sABI undergoing DC.
METHODS: Exploratory clinical trial with pre-test, post-test, and 6 months follow-up assessments. Medical drugs and device are not involved in the study. The design provides only one group of patients who underwent CP.
POPULATION: Patients with sABI treated with DC will be recruited in the Neurorehabilitation Unit of the IRCCS Istituto delle Scienze Neurologiche di Bologna. Subjects will be recruited accordingly to the following eligibility criteria:
- Inclusion Criteria:
- Diagnosis of sABI, a neurological condition due to a severe acquired brain damage (i.e., traumatic brain injury, ischemic stroke, hemorrhagic stroke) with a coma lasting at least 24 hours, according to a Glasgow Coma Scale equal or lower than 8 and/or complex and severe neurological disabilities treatable only in high specialty neurehabilitative settings.
- Early DC, within 24 h;
- Age between 18 and 75 years;
- Intra-hospital rehabilitation setting (ordinary hospitalization or day hospithal);
- Informed consent agreement.
- Exclusion Criteria:
- Medical instability at enrollment, defined as the acute onset of an unexplained derangement of vital parameters (i.e., temperature, blood pressure, pulse rate, respiratory rate, oxygen saturation, level of responsiveness) outside the normal range (for example, fever, acute internist conditions, etc.) and/or the onset of any new medical condition requiring unexpected additional diagnostic procedures and treatments (for example, severe pain, reduction of urinary output, etc.);
- Post-traumatic agitation;
- Dehiscence, in progress, of the DC surgical wound;
- CP already performed;
- Magnetic Resonance Imaging (MRI) absolute contraindications.
INTERVENTION: 3-T MRI scanner with a 64-channel head for structural and functional imaging (Diffusion Tensor Imaging, Tractography and resting state fMRI).
CONTROL: There is no control group, although normative data relating to a population of healthy subjects, matched by sex and age, are used to define normative parameters for functional imaging.
OUTCOMES: Multidisciplinary assessment with clinical and neurophysiological indices. All of the assessment measures will be administrated following the same timing: Pre-test: within 10 days before CP; Post-test: from 30 to 40 days after CP; Follow-up: from 170 to 190 days after CP.
EXPECTED RESULTS: The Study results may inform on the correlation between neurophysiological changes in terms of structural and functional connectivity after DC and long term cognitive, motor and clinical outcomes.
RANDOMIZATION: N/A
ASSESSOR AND PATIENT BLINDNESS: N/A
CASE REPORT AND DATA MONITORING: Specific case report forms (CRF) for every clinical and motor scale in the assessments are already available and will be used. All information about neurophysiological results will be promptly reported on the electronic database. A researcher will be responsible for the electronic database, data analyses and will draft the single patient record at the end of all procedures. In case of lost to follow-up, the information available up to that moment will be considered
SAMPLE SIZE: From the retrospective analysis of hospitalizations carried out in previous years, it is estimated that the incidence of patients with DC is around 23% per year. Therefore, out of a total of about 65 annual hospitalizations, it is estimated that 10 patients can be enrolled within two years.
DATA ANALYSES: Considering the exploratory nature of the study, descriptive statistics in the pre-post and follow-up time points will be reported and compared. The analysis will be performed by one-way ANOVA for continuous variables and Mann-Witney test for ordinal variables
- Being tested
- CP group
- Keywords
- Decompressive Craniectomy, Cranioplasty, MRI, EEG, Functional Connectivity, Structural Connectivity.
- Medical subject headings
- Brain Injuries, Brain Injuries, Traumatic, Ischemic Stroke, Hemorrhagic Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CP groupProcedure or surgery
Pre- post-cranioplasty and 6 months follow-up MRI assessment. Each MRI session lasts about 60 minutes and will measure Diffusion Tensor Imaging, Tractography and resting state fMRI.
| Study group | Role | What they receive |
|---|---|---|
| CP group | Experimental | Pre- post-cranioplasty and 6 months follow-up MRI assessment. Each MRI session lasts about 60 minutes and will measure Diffusion Tensor Imaging, Tractography and resting state fMRI Receives: Procedure: CP group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in Mean Diffusivity values:
- Mean diffusivity (MD) from the Diffusion Tensor Imaging (DTI) data: a measure of brain structural integrity which describes the rotationally invariant magnitude of water diffusion within brain tissues. Higher values indicate worse tissue injury.
Measured: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Secondary outcomes (18)
Changes in fractional anisotropy values
- fractional anisotropy (FA) [0-1] from the Diffusion Tensor Imaging (DTI) data: a measure of brain structural integrity which reflects the directionality of molecular displacement by diffusion. Lower values indicate worse tissue injury.
Measured: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in Cognitive functioning
LCF (Levels of Cognitive Functioning) [1-10]: a single item scale that allows to monitor cognitive and behavioral evolution from coma (LCF1) to the complete social and work reintegration (LCF 10); where higher scores mean a better outcome
Measured: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in disability level
DRS (Disability Rating Scale) [29-0]: an 8 item scale (three of them by Glasgow Coma Scale) that assess clinical changes, where higher ratings indicate a more severe disability
Measured: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in functional independence
FIM (Functional Independence Measure) [18-126]: to assess cognitive and motor abilities, where higher scores mean a better outcome
Measured: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in level of consciousness
CRS-R (Coma Recovery Scale Revised) [0-29]: to measure the behavioral correlates of state of consciousness (in patients with LCF 1-3); higher scores indicate a better outcome
Measured: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in functional abilities
EFA (Early Functional Abilities) [12-60]:to assess cognitive and motor problems in patients with disorders of consciousness or early confusional state (in patients with LCF 1-5); higher scores indicate a better outcome.
Measured: Frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in motor abilities
TCT (Trunk Control Test) [0-100] for trunk control aspects; (in patients with LCF 5-10); higher scores indicate a better outcome
Measured: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in trunk control
UTAS (Unified Trunk Assessment Scale) [0-31]: for trunk control aspects; (in patients with LCF 5-10); higher scores indicate a better outcome
Measured: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in balance control
UBS (Unified Balance Scale) [0-33]: to assess balance and walk; (in patients with LCF 5-10); higher scores indicate a better outcome
Measured: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in Ambulation
FAC (Functional Ambulation Categories) [0-5], WHS [1-6] and 10 meters walking test [sec]: to assess balance and walk; (in patients with LCF 5-10); higher scores indicate a better outcome
Measured: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in walking handicap
WHS (Walking Handicap Scale) [1-6] and 10 meters walking test [sec]: to assess balance and walk; (in patients with LCF 5-10); higher scores indicate a better outcome
Measured: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in walking abilities
10 meters walking test [sec]: to assess balance and walk; (in patients with LCF 5-10); higher scores indicate a better outcome
Measured: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in motor autonomy
Barthel Index [0-100]: concerning the level of motor autonomy in the activities of daily living. Lower scores indicate a better outcome
Measured: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in cognitive level
ConfuScale [0-72]: a brief neuropsychological scale to assess cognitive functioning; (in patients with LCF 4-7); higher scores indicate a better outcome
Measured: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in neuropsychological functions
ACE-R (AddenBrooke's Cognitive Examination-Revised) [0-100]: a brief neuropsychological scale to assess cognitive functioning; (in patients with LCF 4-7); higher scores indicate a better outcome.
Measured: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in Structured neuropsychological assessment
The Extensive neuropsychological battery to test the different cognitive functions (for patients with LCF>7). A z-score greater than 0 indicates an above-average performance
Measured: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in quantitative EEG
AFR score (Amplitude Frequency Reactivity) [0-10]: A standard EEG score for basic assessment of EEG features. higher values indicate a better outcome.
Measured: Frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in EEG connectivity and continuity
Score of the correlation between EEG signals over the scalp electrodes [0-1]. higher scores indicate a better outcome
Measured: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2022
- Study start27 Oct 2020
- Primary completion12 May 2021
- Study completion27 Apr 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acquired Brain InjuryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Azienda Usl di Bologna
- Sponsor type
- Other government
- Collaborators
- Ministero della Salute, Italy
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05440682
- Sponsor's protocol ID
- ISNB-MR&NR-2020-01
- Status last verified
- Jun 2022
- First submitted
- 28 Mar 2022
- Last updated
- 1 Jul 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Jul 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Structural and Functional Connectivity as Outcome Markers of Cranioplasty Following Decompressive Craniectomy
- ClinicalTrials.gov ID
- NCT05440682
- Acronym / sponsor ID
- ISNB-MR&NR-2020-01
- Keywords
- Decompressive Craniectomy, Cranioplasty, MRI, EEG, Functional Connectivity, Structural Connectivity.
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- Azienda Usl di BolognaOther government
- Collaborators
- Ministero della Salute, Italy
- Study start
- 27 Oct 2020 (actual)
- Primary completion
- 12 May 2021 (actual)
- Study completion
- 27 Apr 2023 (estimated)
- First posted
- 1 Jul 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An Exploratory Interventional study to assess the effects of cranioplasty on brain network connectivity, neuropsychological and motor functioning in patients with severe acquired brain injury with pre-, post-cranioplasty and 6 months follow-up assessments.
Detailed description
BACKGROUND: Cranioplasty (CP) refers to the surgical reconstruction of the cranial defect secondary to Decompressive Craniectomy (DC). The aim of this intervention is not only to restore cranial cosmesis and the normal cerebral protection, but also to facilitate neurological rehabilitation.
Clinical improvements after CP, may occur as early as 4 days after the surgical reconstruction of the cranial vault and may include vigilance/consciousness, sensorimotor and cognitive functioning. In particular, several studies showed relevant neurological improvement of motor and cognitive impairments as well as in the disability level in severe acquired brain injury (sABI) patients treated with DC in the acute phase. To date, it is not possible to predict the extent of the expected improvement after CP, and the effects in terms of long-term functional outcome appears to be variable from subject to subject.
The CO-CRAN (COnnectivity in CRANioplasty) study is based on the experimental hypothesis that the extent of recovery could be significantly correlated with the degree of integrity of the neural network, in relation to the primary damage, of the cerebral hemisphere ipsilateral to craniectomy. It is assumed that if the neural network is relatively intact, the extent of the recovery could be maximal. Conversely, when there is an extensive functional impairment of the underlying craniectomy flap, the impairment of the neural network does not allow a maximum recovery.
AIM: The aim of the study is to investigate possible morpho-functional neuroimaging determinants that may be predictive of post-cranioplasty recovery in patients with sABI undergoing DC.
METHODS: Exploratory clinical trial with pre-test, post-test, and 6 months follow-up assessments. Medical drugs and device are not involved in the study. The design provides only one group of patients who underwent CP.
POPULATION: Patients with sABI treated with DC will be recruited in the Neurorehabilitation Unit of the IRCCS Istituto delle Scienze Neurologiche di Bologna. Subjects will be recruited accordingly to the following eligibility criteria:
- Inclusion Criteria:
- Diagnosis of sABI, a neurological condition due to a severe acquired brain damage (i.e., traumatic brain injury, ischemic stroke, hemorrhagic stroke) with a coma lasting at least 24 hours, according to a Glasgow Coma Scale equal or lower than 8 and/or complex and severe neurological disabilities treatable only in high specialty neurehabilitative settings.
- Early DC, within 24 h;
- Age between 18 and 75 years;
- Intra-hospital rehabilitation setting (ordinary hospitalization or day hospithal);
- Informed consent agreement.
- Exclusion Criteria:
- Medical instability at enrollment, defined as the acute onset of an unexplained derangement of vital parameters (i.e., temperature, blood pressure, pulse rate, respiratory rate, oxygen saturation, level of responsiveness) outside the normal range (for example, fever, acute internist conditions, etc.) and/or the onset of any new medical condition requiring unexpected additional diagnostic procedures and treatments (for example, severe pain, reduction of urinary output, etc.);
- Post-traumatic agitation;
- Dehiscence, in progress, of the DC surgical wound;
- CP already performed;
- Magnetic Resonance Imaging (MRI) absolute contraindications.
INTERVENTION: 3-T MRI scanner with a 64-channel head for structural and functional imaging (Diffusion Tensor Imaging, Tractography and resting state fMRI).
CONTROL: There is no control group, although normative data relating to a population of healthy subjects, matched by sex and age, are used to define normative parameters for functional imaging.
OUTCOMES: Multidisciplinary assessment with clinical and neurophysiological indices. All of the assessment measures will be administrated following the same timing: Pre-test: within 10 days before CP; Post-test: from 30 to 40 days after CP; Follow-up: from 170 to 190 days after CP.
EXPECTED RESULTS: The Study results may inform on the correlation between neurophysiological changes in terms of structural and functional connectivity after DC and long term cognitive, motor and clinical outcomes.
RANDOMIZATION: N/A
ASSESSOR AND PATIENT BLINDNESS: N/A
CASE REPORT AND DATA MONITORING: Specific case report forms (CRF) for every clinical and motor scale in the assessments are already available and will be used. All information about neurophysiological results will be promptly reported on the electronic database. A researcher will be responsible for the electronic database, data analyses and will draft the single patient record at the end of all procedures. In case of lost to follow-up, the information available up to that moment will be considered
SAMPLE SIZE: From the retrospective analysis of hospitalizations carried out in previous years, it is estimated that the incidence of patients with DC is around 23% per year. Therefore, out of a total of about 65 annual hospitalizations, it is estimated that 10 patients can be enrolled within two years.
DATA ANALYSES: Considering the exploratory nature of the study, descriptive statistics in the pre-post and follow-up time points will be reported and compared. The analysis will be performed by one-way ANOVA for continuous variables and Mann-Witney test for ordinal variables
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| CP group | Experimental | Procedure: CP groupPre- post-cranioplasty and 6 months follow-up MRI assessment. Each MRI session lasts about 60 minutes and will measure Diffusion Tensor Imaging, Tractography and resting state fMRI |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Diagnosis of sABI, a neurological condition due to a severe acquired brain damage (i.e., traumatic brain injury, ischemic stroke, hemorrhagic stroke) with a coma lasting at least 24 hours, according to a Glasgow Coma Scale equal or lower than 8 and/or complex and severe neurological disabilities treatable only in high specialty neurehabilitative settings.
- Early DC, within 24 h;
- Age between 18 and 75 years;
- Intra-hospital rehabilitation setting (ordinary hospitalization or day hospithal);
- Informed consent agreement.
Key exclusion criteria (5 listed)
- Medical instability at enrollment, defined as the acute onset of an unexplained derangement of vital parameters (i.e., temperature, blood pressure, pulse rate, respiratory rate, oxygen saturation, level of responsiveness) outside the normal range (for example, fever, acute internist conditions, etc.) and/or the onset of any new medical condition requiring unexpected additional diagnostic procedures and treatments (for example, severe pain, reduction of urinary output, etc.);
- Post-traumatic agitation;
- Dehiscence, in progress, of the DC surgical wound;
- CP already performed;
- Magnetic Resonance Imaging (MRI) absolute contraindications.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CP groupPre- post-cranioplasty and 6 months follow-up MRI assessment. Each MRI session lasts about 60 minutes and will measure Diffusion Tensor Imaging, Tractography and resting state fMRI. | Procedure or surgery | CP group |
Primary outcome
Changes in Mean Diffusivity values:
Time frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
- Mean diffusivity (MD) from the Diffusion Tensor Imaging (DTI) data: a measure of brain structural integrity which describes the rotationally invariant magnitude of water diffusion within brain tissues. Higher values indicate worse tissue injury.
18 secondary outcomes
Changes in fractional anisotropy values
Time frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in Cognitive functioning
Time frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in disability level
Time frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in functional independence
Time frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in level of consciousness
Time frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in functional abilities
Time frame: Frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in motor abilities
Time frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in trunk control
Time frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in balance control
Time frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in Ambulation
Time frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in walking handicap
Time frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in walking abilities
Time frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in motor autonomy
Time frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in cognitive level
Time frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in neuropsychological functions
Time frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in Structured neuropsychological assessment
Time frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in quantitative EEG
Time frame: Frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Changes in EEG connectivity and continuity
Time frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2022.
- Individual participant dataSharing planned: No
Related trials for Acquired Brain Injury
RecruitingPhase 3
Efficacy of Propranolol in Traumatic Brain Injury Patients Admitted to the ICU: A Prospective, Randomized, Triple-Blind Study
Traumatic Brain Injury (TBI) Patients
Recruiting
Minimal Sedation Versus Standard Continuous Sedation After Out-of-Hospital Cardiac Arrest
Out-of-Hospital Cardiac Arrest, Hypoxic-Ischemic Brain Injury
Recruiting
Feasibility and Acceptability of an LLM-based Chatbot for Family Caregivers: Evaluation Study
Caregivers
RecruitingPhase 1
Rehabilitation Through Virtual Immersion & Integrated Exposure for Mild Traumatic Brain Injury (ReVIVE for mTBI)
Traumatic Brain Injuries, TBI (Traumatic Brain Injury)
Recruiting
Amnioinfusion's Protective Effects on Respiratory and Longitudinal Pediatric Outcomes After Intrapartum Meconium Exposure
Neonatal Respiratory Distress Related Conditions, Meconium
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CP group in people with Acquired Brain Injury and Traumatic Brain Injury, run by Azienda Usl di Bologna at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 1 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Fabio La Porta, Md (051 622 5111, fabiolaporta@mail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in Mean Diffusivity values: (time frame: pre-test: within 10 days before CP - post-test: from 30 to 40 days after CP - follow-up: from 170 to 190 days after CP). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2022.